Literature DB >> 2822596

Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).

G J Peters1, S L Sharma, E Laurensse, H M Pinedo.   

Abstract

The mechanism of action of NSC 368390 (DUP-785, 6-fluoro-2-(2'-fluoro-1, 1'-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt) was studied using three different approaches. First, we studied growth inhibition by DUP-785 in L1210 leukemia cells and M5 melanoma cells. The concentrations causing 50% growth inhibition after 48 hr of culture were 5.8 and 0.6 microM, respectively. DUP-785 had to be present continuously throughout culture. Growth inhibition by 25 microM DUP-785 could be prevented by addition of 1 mM uridine or orotic acid to cultures of these cell lines; in M5 cells cytidine was also able to prevent growth inhibition. Dihydro-orotic acid (DHO) and carbamyl-aspartate were not able to prevent growth inhibition by DUP-785. Second, we studied accumulation of orotic acid and of orotidine induced by incubation with 1 microM pyrazofurin, an inhibitor of the orotate phosphoribosyl-transferase-orotidine-monophosphate decarboxylase complex. Addition of DUP-785 to the culture medium prevented the orotic acid accumulation. Furthermore, DUP-785 prevented accumulation of H14CO3- into orotic acid of pyrazofurin-treated L1210 cells. Third, we measured the effect of DUP-785 on DHO-dehydrogenase (DHO-DH), since the results indicated that this enzyme was affected by DUP-785. DHO-DH was assayed in isolated rat liver mitochondria. The Km for L-DHO was about 12 microM. DUP-785 appeared to be a potent inhibitor of DHO-DH with an apparent Ki of about 0.1 microM and an apparent Ki' of about 0.8 microM. The mode of inhibition appeared to be linear mixed type. After exposure of L1210 cells to 25 microM DUP-785 for 2 hr DHO-DH was almost completely inhibited. After suspension in fresh medium without drug, DHO-DH activity was recovered to about 60% after 24 hr. In conclusion, DUP-785 is a potent inhibitor of pyrimidine de novo biosynthesis, by inhibition of the mitochondrial enzyme DHO-DH.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822596     DOI: 10.1007/BF00175293

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  23 in total

1.  Inhibition of synthesis of pyrimidine nucleotides by 2-hydroxy-3-(3,3-dichloroallyl)-1,4-naphthoquinone.

Authors:  L L Bennett; D Smithers; L M Rose; D J Adamson; H J Thomas
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

2.  Mechanism of allopurinol-mediated inhibition and stabilization of human orotate phosphoribosyltransferase and orotidine phosphate decarboxylase.

Authors:  W J Tax; J H Veerkamp; F J Trijbels; E D Schretlen
Journal:  Biochem Pharmacol       Date:  1976-09-15       Impact factor: 5.858

3.  Clinical, biological, and biochemical effect of pyrazofurin.

Authors:  E C Cadman; D E Dix; R E Handschumacher
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

4.  Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.

Authors:  J D Moyer; R E Handschumacher
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

Review 5.  Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.

Authors:  G Weber
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

6.  Separation of 5-fluorouracil and uracil by ion-pair reversed-phase high-performance liquid chromatography on a column with porous polymeric packing.

Authors:  G J Peters; I Kraal; E Laurensse; A Leyva; H M Pinedo
Journal:  J Chromatogr       Date:  1984-05-11

7.  A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors.

Authors:  A Cornish-Bowden
Journal:  Biochem J       Date:  1974-01       Impact factor: 3.857

8.  Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.

Authors:  D L Dexter; D P Hesson; R J Ardecky; G V Rao; D L Tippett; B A Dusak; K D Paull; J Plowman; B M DeLarco; V L Narayanan
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

9.  Purification and properties of the bovine liver mitochondrial dihydroorotate dehydrogenase.

Authors:  V Hines; L D Keys; M Johnston
Journal:  J Biol Chem       Date:  1986-08-25       Impact factor: 5.157

10.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

View more
  22 in total

1.  Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors.

Authors:  A Zeevi; G Z Yao; R Venkataramanan; R J Duquesnoy; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

2.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

3.  Potentiation of the antiproliferative activity of brequinar sodium for murine lymphocytes by exogenous cytidine.

Authors:  A W Thomson; J Woo; B Lemster; S Todo; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

4.  Cytidine potentiates the inhibitory effect of brequinar sodium on concordant cardiac xenograft rejection.

Authors:  M Catena; J Woo; L A Valdivia; S Celli; F Pan; J J Fung; T E Starzl; A W Thompson
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

5.  Localization of dihydroorotate oxidase in myocardium and kidney cortex of the rat. An electron microscopic study using the cerium technique.

Authors:  S Angermüller; M Löffler
Journal:  Histochem Cell Biol       Date:  1995-04       Impact factor: 4.304

6.  Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells.

Authors:  K Tamura; J Woo; M T Bakri; A W Thomson
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

7.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production.

Authors:  J Woo; B Lemster; K Tamura; T E Starzl; A W Thomson
Journal:  Transplantation       Date:  1993-08       Impact factor: 4.939

9.  Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Authors:  H A Burris; E Raymond; A Awada; J G Kuhn; T J O'Rourke; J Brentzel; W Lynch; S Y King; T D Brown; D D Von Hoff
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

10.  Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.

Authors:  G Schwartsmann; P Dodion; J B Vermorken; W W ten Bokkel Huinink; J Joggi; B Winograd; H Gall; G Simonetti; W J van der Vijgh; M B van Hennik
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.